Oxalic Acid

Oxalic Acid

SCHEMBL8794397

O=C([O-])C(=O)O.[H+]

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

OPRM1SLC6A4

The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Oxalic Acid SCHEMBL4193055 0.95
Oxalic Acid SCHEMBL7522001 0.95
Oxalic Acid SCHEMBL337153 0.95
Oxalic Acid SCHEMBL106863 0.95
Oxalic Acid SCHEMBL4871484 0.91
Oxalic Acid SCHEMBL23803723 0.90 CA4 (0.50)
Oxalic Acid SCHEMBL1698277 0.90 CA4 (0.50)
Oxalic Acid SCHEMBL104229 0.90
Oxalic Acid SCHEMBL6840041 0.90
Oxalic Acid SCHEMBL20553206 0.90

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3777856-B1 HYDROPHILIC BERBERINE-TYPE DERIVATIVE AND APPLICATION THEREOF IN PREPARING DRUG INST MATERIA MEDICA CAMS (CN) 2022-02-09 EP claimed
EP-3390421-B1 METAL COMPLEXES UNIV LEEDS INNOVATIONS LTD (GB) 2020-01-29 EP claimed
EP-1747188-B1 METHOD FOR THE PRODUCTION OF LONG-CHAINED QUATERNARY AMMONIUM OXALATES AND AMMONIUM HYDROGENOXALATES CLARIANT PRODUKTE DEUTSCHLAND (DE) 2015-07-08 EP claimed
EP-2114118-B1 SAFEGUARDING SEED SAFETY OF TREATED SEEDS BAYER CROPSCIENCE AG (DE) 2012-09-12 EP claimed
EP-0210885-B1 DERIVATIVES OF PRIMARY HALOBIPHENYL ALCOHOLS THERAPEUTICALLY USEFUL IN THE TREATMENT OF ARTERIOSCLEROSIS PIERRE FABRE MEDICAMENT (FR) 1990-07-11 EP claimed
EP-0210885-A1 Derivatives of primary halobiphenyl alcohols therapeutically useful in the treatment of arteriosclerosis PIERRE FABRE MEDICAMENT (FR) 1987-02-04 EP claimed
EP-0000825-B1 GEMINALLY DISUBSTITUTED INDENE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM Kabi AB (SE) 1982-04-14 EP claimed
WO-2024054973-A3 TRYPTAMINE DERIVATIVES CAAMTECH, INC (US) 2024-04-18 WO disclosed
WO-2024054973-A2 TRYPTAMINE DERIVATIVES CAAMTECH, INC (US) 2024-03-14 WO disclosed
EP-0760811-A1 IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H 3? (ANT)AGONISTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) 1997-03-12 EP disclosed
WO-1996029315-A2 IMIDAZOLE DERIVATIVES AS HISTAMINE RECEPTOR H3 (ANT)AGONISTS INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (FR) 1996-09-26 WO disclosed
EP-0210885-B1 DERIVATIVES OF PRIMARY HALOBIPHENYL ALCOHOLS THERAPEUTICALLY USEFUL IN THE TREATMENT OF ARTERIOSCLEROSIS PIERRE FABRE MEDICAMENT (FR) 1990-07-11 EP disclosed
EP-0210885-A1 Derivatives of primary halobiphenyl alcohols therapeutically useful in the treatment of arteriosclerosis PIERRE FABRE MEDICAMENT (FR) 1987-02-04 EP disclosed